COPD. Future plans focus
on FDA approval and the
expansion of the diagnostic
technology to all respiratory
diseases.
The mobile health
marketplace is growing fast,
expanding to more than
100,000 apps. Market revenue
is projected to exceed $26
billion by 2018.
Dr. Richard Gliklich, with the
venture capital firm General
Catalyst Partners, says that
investors are looking for
apps that have something
that more than one of the
healthcare stakeholders will be
willing to pay for. A diagnostic
app that effectively addresses
such a widespread problem as
respiratory diseases appears
to satisfy that criteria.
Potential Challenges
There are potential legal
issues, particularly in the
U.S. Liability questions for
incorrect diagnoses are
undecided. Undoubtedly many
doctors would resist a process
change, but management of
large healthcare organizations
should be approachable
because of the cost savings
and preventive health
applications. Clinical testing
to date has had a high level of
correct diagnosis with asthma
and pneumonia, but it is
unknown if this will prove true
with other diseases.
ResApp
ResApp Health is in the
forefront of mobile healthcare
with the development of this
app that allows someone
to receive a diagnosis of
a respiratory problem by
coughing into a smartphone.
This app addresses a
worldwide problem with a
low-cost, effective solution.
There appear to be many
valid applications for this
technology.
Information sourced from:
startup smart, news.com.au,
ResApp Health and
Business News
June 2018 | VENTURE Innovation | 23
The mobile health marketplace is growing fast,
expanding to more than 100,000 apps. Market
revenue is projected to reach $26 billion by 2017.
widespread. There is ample
reason to believe that a
diagnostic app for respiratory
diseases would be welcomed
and used.
The Future of
Healthcare Apps
ResApp Health is initially
targeting bronchitis,
pneumonia, asthma, and